Spots Global Cancer Trial Database for Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

Official Title: Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

Study ID: NCT05721300

Conditions

Hepatocellular Carcinoma

Chronic Hepatitis B

Interventions

NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） combined with interferon treatments

NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） treatments

Study Description

Brief Summary: The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are: 1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment; 2. Repetitive effect and time effect of different drug treatment at different follow-up time points; 3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon; 4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination. Researchers will compare control group to see if occurrence of liver cancer.

Detailed Description: